Literature DB >> 21282188

Mutations in PPIB (cyclophilin B) delay type I procollagen chain association and result in perinatal lethal to moderate osteogenesis imperfecta phenotypes.

Shawna M Pyott1, Ulrike Schwarze, Helena E Christiansen, Melanie G Pepin, Dru F Leistritz, Richard Dineen, Catharine Harris, Barbara K Burton, Brad Angle, Katherine Kim, Michael D Sussman, Maryann Weis, David R Eyre, David W Russell, Kevin J McCarthy, Robert D Steiner, Peter H Byers.   

Abstract

Recessive mutations in the cartilage-associated protein (CRTAP), leucine proline-enriched proteoglycan 1 (LEPRE1) and peptidyl prolyl cis-trans isomerase B (PPIB) genes result in phenotypes that range from lethal in the perinatal period to severe deforming osteogenesis imperfecta (OI). These genes encode CRTAP (encoded by CRTAP), prolyl 3-hydroxylase 1 (P3H1; encoded by LEPRE1) and cyclophilin B (CYPB; encoded by PPIB), which reside in the rough endoplasmic reticulum (RER) and can form a complex involved in prolyl 3-hydroxylation in type I procollagen. CYPB, a prolyl cis-trans isomerase, has been thought to drive the prolyl-containing peptide bonds to the trans configuration needed for triple helix formation. Here, we describe mutations in PPIB identified in cells from three individuals with OI. Cultured dermal fibroblasts from the most severely affected infant make some overmodified type I procollagen molecules. Proα1(I) chains are slow to assemble into trimers, and abnormal procollagen molecules concentrate in the RER, and bind to protein disulfide isomerase (PDI) and prolyl 4-hydroxylase 1 (P4H1). These findings suggest that although CYPB plays a role in helix formation another effect is on folding of the C-terminal propeptide and trimer formation. The extent of procollagen accumulation and PDI/P4H1 binding differs among cells with mutations in PPIB, CRTAP and LEPRE1 with the greatest amount in PPIB-deficient cells and the least in LEPRE1-deficient cells. These findings suggest that prolyl cis-trans isomerase may be required to effectively fold the proline-rich regions of the C-terminal propeptide to allow proα chain association and suggest an order of action for CRTAP, P3H1 and CYPB in procollagen biosynthesis and pathogenesis of OI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21282188      PMCID: PMC3063987          DOI: 10.1093/hmg/ddr037

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  41 in total

1.  Altered triple helical structure of type I procollagen in lethal perinatal osteogenesis imperfecta.

Authors:  J Bonadio; K A Holbrook; R E Gelinas; J Jacob; P H Byers
Journal:  J Biol Chem       Date:  1985-02-10       Impact factor: 5.157

2.  Identification of disulfide bonds in carboxy-terminal propeptides of human type I procollagen.

Authors:  J Koivu
Journal:  FEBS Lett       Date:  1987-02-23       Impact factor: 4.124

3.  The thermal transition of a non-hydroxylated form of collagen. Evidence for a role for hydroxyproline in stabilizing the triple-helix of collagen.

Authors:  R A Berg; D J Prockop
Journal:  Biochem Biophys Res Commun       Date:  1973-05-01       Impact factor: 3.575

4.  The role of cis-trans isomerization of peptide bonds in the coil leads to and comes from triple helix conversion of collagen.

Authors:  H P Bächinger; P Bruckner; R Timpl; J Engel
Journal:  Eur J Biochem       Date:  1978-10-16

5.  Human cyclophilin B: a second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence.

Authors:  E R Price; L D Zydowsky; M J Jin; C H Baker; F D McKeon; C T Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

6.  Cysteine in the triple-helical domain of one allelic product of the alpha 1(I) gene of type I collagen produces a lethal form of osteogenesis imperfecta.

Authors:  B Steinmann; V H Rao; A Vogel; P Bruckner; R Gitzelmann; P H Byers
Journal:  J Biol Chem       Date:  1984-09-10       Impact factor: 5.157

7.  The Mr 24,000 phosphoprotein from developing bone is the NH2-terminal propeptide of the alpha 1 chain of type I collagen.

Authors:  L W Fisher; P G Robey; N Tuross; A S Otsuka; D A Tepen; F S Esch; S Shimasaki; J D Termine
Journal:  J Biol Chem       Date:  1987-10-05       Impact factor: 5.157

8.  Detection of cis and trans X-Pro peptide bonds in proteins by 13C NMR: application to collagen.

Authors:  S K Sarkar; P E Young; C E Sullivan; D A Torchia
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

9.  Cyclosporin A slows collagen triple-helix formation in vivo: indirect evidence for a physiologic role of peptidyl-prolyl cis-trans-isomerase.

Authors:  B Steinmann; P Bruckner; A Superti-Furga
Journal:  J Biol Chem       Date:  1991-01-15       Impact factor: 5.157

10.  Prolyl 3-hydroxylase 1, enzyme characterization and identification of a novel family of enzymes.

Authors:  Janice A Vranka; Lynn Y Sakai; Hans Peter Bächinger
Journal:  J Biol Chem       Date:  2004-03-24       Impact factor: 5.157

View more
  42 in total

Review 1.  Protein secretion and the endoplasmic reticulum.

Authors:  Adam M Benham
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-08-01       Impact factor: 10.005

2.  Deficiency of CRTAP in non-lethal recessive osteogenesis imperfecta reduces collagen deposition into matrix.

Authors:  M Valli; A M Barnes; A Gallanti; W A Cabral; S Viglio; M A Weis; E Makareeva; D Eyre; S Leikin; F Antoniazzi; J C Marini; M Mottes
Journal:  Clin Genet       Date:  2011-10-19       Impact factor: 4.438

3.  Specialisation of extracellular matrix for function in tendons and ligaments.

Authors:  Helen L Birch; Chavaunne T Thorpe; Adam P Rumian
Journal:  Muscles Ligaments Tendons J       Date:  2013-05-21

4.  A transgenic mouse model of OI type V supports a neomorphic mechanism of the IFITM5 mutation.

Authors:  Caressa D Lietman; Ronit Marom; Elda Munivez; Terry K Bertin; Ming-Ming Jiang; Yuqing Chen; Brian Dawson; Mary Ann Weis; David Eyre; Brendan Lee
Journal:  J Bone Miner Res       Date:  2015-03       Impact factor: 6.741

5.  A substrate preference for the rough endoplasmic reticulum resident protein FKBP22 during collagen biosynthesis.

Authors:  Yoshihiro Ishikawa; Hans Peter Bächinger
Journal:  J Biol Chem       Date:  2014-05-12       Impact factor: 5.157

6.  Cole-Carpenter syndrome is caused by a heterozygous missense mutation in P4HB.

Authors:  Frank Rauch; Somayyeh Fahiminiya; Jacek Majewski; Jian Carrot-Zhang; Sergei Boudko; Francis Glorieux; John S Mort; Hans-Peter Bächinger; Pierre Moffatt
Journal:  Am J Hum Genet       Date:  2015-02-12       Impact factor: 11.025

7.  Connective tissue alterations in Fkbp10-/- mice.

Authors:  Caressa D Lietman; Abbhirami Rajagopal; Erica P Homan; Elda Munivez; Ming-Ming Jiang; Terry K Bertin; Yuqing Chen; John Hicks; MaryAnn Weis; David Eyre; Brendan Lee; Deborah Krakow
Journal:  Hum Mol Genet       Date:  2014-04-28       Impact factor: 6.150

8.  An additional function of the rough endoplasmic reticulum protein complex prolyl 3-hydroxylase 1·cartilage-associated protein·cyclophilin B: the CXXXC motif reveals disulfide isomerase activity in vitro.

Authors:  Yoshihiro Ishikawa; Hans Peter Bächinger
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

9.  WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta.

Authors:  Shawna M Pyott; Thao T Tran; Dru F Leistritz; Melanie G Pepin; Nancy J Mendelsohn; Renee T Temme; Bridget A Fernandez; Solaf M Elsayed; Ezzat Elsobky; Ishwar Verma; Sreelata Nair; Emily H Turner; Joshua D Smith; Gail P Jarvik; Peter H Byers
Journal:  Am J Hum Genet       Date:  2013-03-14       Impact factor: 11.025

10.  Comprehensive mass spectrometric mapping of the hydroxylated amino acid residues of the α1(V) collagen chain.

Authors:  Chenxi Yang; Arick C Park; Nicholas A Davis; Jason D Russell; Byoungjae Kim; David D Brand; Matthew J Lawrence; Ying Ge; Michael S Westphall; Joshua J Coon; Daniel S Greenspan
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.